Benzinga | Apr 8, 2021 09:09AM EDT

Portage Biotech Doses First Patient In PRECIOUS-01 Study Of PORT-3 For Treatment Of NY-ESO-1 Positive Solid Tumors

Portage Biotech Inc. (NASDAQ:PRTG) (CSE:PBT) ("Portage" or the "Company"), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that the first patient has been dosed in the Phase 1 portion of the PRECIOUS-01 open-label, dose-escalation and expansion clinical trial assessing the safety, tolerability, efficacy and dosing of PORT-3 in the treatment of cancer.